Phase III trials of the intravenous drug ibalizumab have been found to significantly reduce viral load in people living with HIV who do not respond to existing treatment.

HIV criminalisation is a growing global issue that is threatening effective HIV prevention, treatment and support, according to a new report from the HIV Justice Network and the Global Network of People Living with HIV (GNP+).